- Home
- XMTR vs SUPN Comparison
XMTR vs SUPN Comparison
Compare XMTR & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XMTR
- SUPN
- Stock Information
- Founded
- XMTR 2013
- SUPN 2005
- Country
- XMTR United States
- SUPN United States
- Employees
- XMTR N/A
- SUPN N/A
- Industry
- XMTR Industrial Machinery/Components
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- XMTR Technology
- SUPN Health Care
- Exchange
- XMTR Nasdaq
- SUPN Nasdaq
- Market Cap
- XMTR 1.6B
- SUPN 1.8B
- IPO Year
- XMTR 2021
- SUPN 2012
- Fundamental
- Price
- XMTR $32.62
- SUPN $33.58
- Analyst Decision
- XMTR Buy
- SUPN Hold
- Analyst Count
- XMTR 11
- SUPN 2
- Target Price
- XMTR $34.82
- SUPN $36.00
- AVG Volume (30 Days)
- XMTR 605.9K
- SUPN 733.3K
- Earning Date
- XMTR 08-07-2025
- SUPN 08-05-2025
- Dividend Yield
- XMTR N/A
- SUPN N/A
- EPS Growth
- XMTR N/A
- SUPN N/A
- EPS
- XMTR N/A
- SUPN 1.11
- Revenue
- XMTR $573,810,000.00
- SUPN $667,997,000.00
- Revenue This Year
- XMTR $21.52
- SUPN N/A
- Revenue Next Year
- XMTR $17.20
- SUPN $12.02
- P/E Ratio
- XMTR N/A
- SUPN $30.34
- Revenue Growth
- XMTR 19.35
- SUPN 11.82
- 52 Week Low
- XMTR $11.33
- SUPN $27.05
- 52 Week High
- XMTR $45.33
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- XMTR 46.64
- SUPN 57.52
- Support Level
- XMTR $31.62
- SUPN $32.51
- Resistance Level
- XMTR $36.08
- SUPN $33.72
- Average True Range (ATR)
- XMTR 1.72
- SUPN 1.08
- MACD
- XMTR -0.37
- SUPN 0.03
- Stochastic Oscillator
- XMTR 22.18
- SUPN 72.94
About XMTR Xometry Inc.
Xometry Inc is engaged in providing AI-enabled manufacturing equipment. Its buyers include engineers, product designers, procurement and supply chain personnel, inventors, and business owners. The manufacturing processes offered by the company include CNC Machining, Injection Molding, Urethane Casting, 3D Printing, and Die Casting. The company is organized into two segments referred to as the U.S. and the International. The majority of its revenue is derived from the U.S. segment.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.